Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CYP3A4 and CYP3A5 genotyping by Pyrosequencing.

Adam A Garsa1, Howard L McLeod, Sharon Marsh

  • 1Washington University School of Medicine, Department of Medicine, Division of Oncology, St. Louis, MO 63110, USA.

BMC Medical Genetics
|May 11, 2005
PubMed
Summary

Genetic variations in cytochrome P450 3A enzymes (CYP3A4 and CYP3A5) significantly impact drug metabolism. Pyrosequencing assays revealed substantial interethnic differences in key single nucleotide polymorphism (SNP) frequencies, crucial for personalized medicine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

JCO precision oncology·2026
Same author

Propranolol metabolite and enantiomers affect colorectal cancer development by inhibiting MAPK pathway and downregulating PD-1 expression.

International immunopharmacology·2025
Same author

A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors.

Cancer letters·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025
Same author

Causal effects of immune cells on the efficacy and adverse drug reactions of platinum drugs.

Acta biochimica et biophysica Sinica·2025
Same author

Pharmacogenomics in Oncology-Running Out of Excuses for Slow Adoption.

JAMA network open·2024

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Genetic Variation

Background:

  • Cytochrome P450 3A enzymes (CYP3A4, CYP3A5) are critical for drug metabolism.
  • Significant interindividual variability in CYP3A expression is linked to genetic factors.
  • This study focuses on key single nucleotide polymorphisms (SNPs) in CYP3A4 and CYP3A5.

Purpose of the Study:

  • To develop and validate Pyrosequencing assays for specific CYP3A4 and CYP3A5 SNPs.
  • To investigate the allele frequencies of these SNPs in European and African populations.
  • To assess interethnic variations in genetic markers relevant to drug metabolism.

Main Methods:

  • Pyrosequencing was employed for genotyping.
  • 95 healthy European and 95 healthy African volunteers were analyzed.

Related Experiment Videos

  • Linkage disequilibrium, haplotype inference, and Hardy-Weinberg equilibrium were determined.

    • Main Results:

    • Significant interethnic differences were observed in allele frequencies for CYP3A4*1B, CYP3A4*3, CYP3A5*3C, and CYP3A5*6.
    • CYP3A4*1B was 4% in Europeans vs. 82% in Africans; CYP3A5*3C was 94% in Europeans vs. 12% in Africans.
    • CYP3A5*6 was found in 16% of Africans but not in Europeans, underscoring ethnic disparities.

    Conclusions:

    • Pyrosequencing is an effective method for SNP analysis in pharmacogenomic research.
    • Understanding ethnic variations in CYP3A SNPs is essential for personalized drug therapy.
    • This technique can aid in pre-screening patients for tailored treatment selection.